SCHEMBL16655016

SCHEMBL16655016

Cc1cc(N)ccc1C(=O)N1CCC(Nc2ncc(Cl)c(-c3cn(S(=O)(=O)c4ccccc4)c4ccccc34)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 11/20 0.46
MAPK9 P45984 11/20 0.46
MAPK10 P53779 7/20 0.46
CDK2 P24941 12/20 0.45
JUN P05412 10/20 0.45
CCNA2 P20248 1/20 0.43
CCNA1 P78396 1/20 0.43
CDK7 P50613 3/20 0.43
CCNT1 O60563 2/20 0.43
CDK9 P50750 2/20 0.43
CCNH P51946 2/20 0.43
MNAT1 P51948 2/20 0.43
EGFR P00533 1/20 0.42
HTR6 P50406 4/20 0.42
DRD2 P14416 2/20 0.42
HTR2A P28223 1/20 0.42
HTR7 P34969 1/20 0.42
CCNE1 P24864 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16654752 0.92 CDK7 (0.49) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16654978 0.91 HTR6 (0.46) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16655007 0.90 CDK2 (0.46) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16655351 0.90 MAPK8 (0.45) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16654808 0.86 CDK2 (0.48) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16654810 0.86 CDK2 (0.48) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16655415 0.86 CDK2 (0.48) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16655134 0.85 CDK7 (0.48) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16655044 0.85 MEN1 (0.45) MAPK8MAPK9MAPK10CDK2JUN
SCHEMBL16655226 0.83 TNFSF11 (0.49) MAPK8MAPK9MAPK10CDK2JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190292167-A1 HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2019-09-26 US disclosed
US-20190292167-A1 HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2019-09-26 US disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
EP-3057954-A2 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Syros Pharmaceuticals, Inc. (US) 2016-08-24 EP disclosed
WO-2015058163-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-04-23 WO disclosed
WO-2015058163-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292167-A1 HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES CDK7, CDK3, CDK17 MAPK8 352/4885MAPK9 506/4885MAPK10 1057/4885
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES CDK7, CDK6, CDK3 MAPK8 532/4885MAPK9 599/4885MAPK10 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.